Ranbaxy gets tentative FDA approval to market oral schizophrenia drug

By Elaine Rigoli

Tampa, Fla., Aug. 4 - Ranbaxy Laboratories, Ltd. received tentative approval from the Food and Drug Administration to manufacture risperidone oral solution 1 mg/ml for the treatment of schizophrenia.

The company said total annual market sales for risperidone oral solution average $66 million.

"This product represents a future opportunity for Ranbaxy and will be launched following final approval from FDA," vice president of sales and marketing Jim Meehan said in a news release.

Ranbaxy, through its wholly owned subsidiary Ranbaxy Pharmaceutical, Inc., is a pharmaceutical company with offices in Jacksonville, Fla.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.